Cancer Models

Assuming you have already passed through the screening of different lids by our in-vitro screening services, you probably already thought about your next step-in-vivo studies. The spectrum of preclinical cancer models is quite wide, and selecting the correct study model is fundamental. For instance, an immune-checkpoint inhibitor (ICI) candidate can be tested only in a model where all the components of the immune system are present, i.e, a syngeneic cancer model.

Similarly, an antibody-based- or a cell-based-therapy for a human tumor expressing the specific target, can only be tested in a model where the target receptor is expressed, e.g. the human tumor engrafted in an immunodeficient mouse (tumor xenograft). The immunodeficient status of the recipient animals is also a key factor, not only for engraving the human tumor but also to engraft the treating cells.

We are indeed fortunate today to have access to a vast variety of laboratory rodents, from inbred and outbred strains, through different strains of immunocompetent animals until a diverse range of rodents (rat and mice in particular) with immunodeficiencies is achieved.

We, at Pharmaseed, have been accumulating many years of experience with an extensive and increasing list of animal models used in the evaluation of different treatment modalities.

Tumor follow-up is another challenging aspect of cancer modeling in preclinical studies. While the simple subcutaneous models have the big advantage of being able to be tracked very easily by a mere caliper measurement, orthotopic models will require an extra level of complexity, not only for the implantation (usually surgical) procedure but rather for tumor follow-up. At Pharmaseed, we provide different options for orthotopic tumor screening, including MRI, Micro-CT with 3D reconstruction and bioluminescence or fluorescence IVIS, depending on the chosen model.

Our services support an array of therapeutic disciplines

Cannabis based therapy

Microbiome

Pharmaceuticals

Medical devices

Biological therapy

Nutraceuticals

Cell & Gene based Therapy

Cancer Models

  • Cancers available: Breast, Glioblastoma, Lung,  Melanoma, Pancreas
  • Species available: Mouse, Rat, Pig
  • Standard assessments: Body weight, clinical signs, tumor measurement (caliper or imaging)
  • Additional assessments: Histology, tumor markers (ELISA, immunostaining), PCR
  • Cancers available: Patient-derived xenograft Leukemia, Lymphoma, Myeloma
  • Species available: Mouse
  • Standard assessments: Body weight, clinical signs, tumor measurement (caliper or imaging)
  • Additional assessments: Histology, tumor markers (ELISA, immunostaining), PCR
  • Cancers available: Bladder, Breast, Cholangiocarcinoma, Colon, Glioblastoma, Liver, Lung, Melanoma, Pancreas, Pituitary, Prostate, Skin, Tongue
  • Species available: Mouse
  • Standard assessments: Body weight, clinical signs, tumor measurement (caliper)
  • Additional assessments: Histology, tumor markers (ELISA, immunostaining), PCR
  • Cancers available: Breast, Lung, Melanoma
  • Species available: Mouse
  • Standard assessments: Body weight, clinical signs, tumor measurement (imaging)
  • Additional assessments: Histology, tumor markers (ELISA, immunostaining), PCR
  • Cancers available: Patient-derived xenograft Leukemia, Lymphoma, Myeloma
  • Species available: Mouse
  • Standard assessments: Body weight, clinical signs, tumor measurement (caliper or imaging)
  • Additional assessments: Histology, tumor markers (ELISA, immunostaining), PCR
  • Cancers available: Colon, Uterus 
  • Species available: Pig, Sheep
  • Standard assessments: Body weight, clinical signs, tumor measurement
  • Additional assessments: Histology, tumor markers (ELISA, immunostaining)
  • Species available: Pig
  • Standard assessments: Body weight, clinical signs, tumor measurement, erythema & edema
  • Additional assessments: Histology, tumor markers (ELISA, immunostaining)
  • Species available for PBMCs: Human, Mouse
  • Cell lines available: More than 60 human & mouse cell lines
  • Standard assessments: MTT, XTT, BrdU, CellTiter-Glo, flow cytometry
  • Cell lines available: More than 100 human & mouse cell lines
  • Standard assessments: MTT, XTT, BrdU, CellTiter-Glo, flow cytometry

Research outcomes - examples

Get in touch